Are you Dr. Lauring?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 38 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
650 W 168th St
Bb-1427 Dept Pathology Columbia University
New York, NY 10032Phone+1 212-305-0395Fax+1 212-305-5498
Summary
- Dr. Brett Lauring, MD is a board certified pathologist in New York, New York. He is currently licensed to practice medicine in New York.
Education & Training
New York Presbyterian Hospital (Cornell Campus)Residency, Pathology-Anatomic and Clinical, 1996 - 2001
New York University School of MedicineClass of 1996
Certifications & Licensure
NY State Medical License 1997 - 2021- American Board of Pathology Anatomic Pathology
Publications & Presentations
PubMed
- 121 citationsEffect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (...Julio Rosenstock, Juan P. Frias, Dénes Páll, Bernard Charbonnel, Raluca Pascu
Diabetes, Obesity & Metabolism. 2018-03-01 - 97 citationsErtugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study.George Grunberger, Sarah Camp, Jeremy Johnson, Susan Huyck, Steven G. Terra
Diabetes Therapy. 2018-02-01 - 102 citationsInteraction of two hereditary spastic paraplegia gene products, spastin and atlastin, suggests a common pathway for axonal maintenanceKatia J. Evans, Christian W. Keller, Karen S. Pavur, Kristen Glasgow, Bryan Conn
Proceedings of the National Academy of Sciences of the United States of America. 2006-07-11
Press Mentions
Kallyope Inc. Appoints Brett Lauring as Chief Medical OfficerFebruary 5th, 2019
Kallyope Enters Phase 2 with First-in-Class Oral Approach for the Treatment of Both Obesity and Type 2 DiabetesSeptember 28th, 2023- Kallyope to Expand Its Metabolic Disorder Programme GloballyOctober 26th, 2023
